Recap: aTyr Pharma Q4 Earnings
Portfolio Pulse from Benzinga Insights
aTyr Pharma (NASDAQ:LIFE) reported Q4 earnings with a miss on estimated earnings by -4.0%, posting an EPS of $-0.25 against an estimate of $-0.24. Revenue decreased by $10.39 million from the same period last year. In the previous quarter, the company exceeded EPS estimates which was followed by a 3.0% drop in share price the next day.
March 14, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
aTyr Pharma reported a Q4 earnings miss with an EPS of $-0.25, missing estimates by 4.0%, and a significant revenue drop from the previous year.
The earnings miss and significant year-over-year revenue drop are likely to negatively impact investor sentiment and could lead to a decrease in stock price, similar to the previous quarter's earnings beat followed by a share price drop.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100